2022
The Impact of Reducing Nicotine Content on Adolescent Cigarette Smoking and Nicotine Exposure: Results From a Randomized Controlled Trial
Cassidy R, Tidey J, Jackson K, Cioe P, Murphy S, Krishnan-Sarin S, Hatsukami D, Colby S. The Impact of Reducing Nicotine Content on Adolescent Cigarette Smoking and Nicotine Exposure: Results From a Randomized Controlled Trial. Nicotine & Tobacco Research 2022, 25: 918-927. PMID: 36482794, PMCID: PMC10077938, DOI: 10.1093/ntr/ntac279.Peer-Reviewed Original ResearchConceptsVLNC cigarettesAdolescent daily smokersNNC cigarettesCigarette smokingDaily smokersWeek 3First clinical trialSources of nicotineNicotine contentLow nicotine contentAdolescent cigarette smokingRespiratory symptomsSecondary outcomesPrimary outcomeControlled TrialsNicotine exposureTotal cigarettesIncomplete adherenceNicotine cigarettesClinical trialsAdolescent smokersTwo-armUS FoodControl groupDrug AdministrationVoluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission
Vermund S. Voluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission. Current HIV/AIDS Reports 2022, 19: 471-473. PMID: 36478080, PMCID: PMC10767716, DOI: 10.1007/s11904-022-00631-z.Peer-Reviewed Original ResearchConceptsHIV acquisitionVoluntary medical male circumcisionHIV infection acquisitionVoluntary medical male circumcision (VMMC) programsMinor surgical interventionsMale circumcision programsHIV incidence ratesHigh HIV prevalenceMedical male circumcisionFirst clinical trialUninfected menHIV incidenceHIV prevalenceInfection acquisitionSaharan AfricaSurgical interventionCircumcision programsClinical trialsIncidence ratePreventive benefitsHIV riskCircumcision ratesRecent FindingsSinceMale circumcisionHealth section
2017
Discontinuing a non-steroidal anti-inflammatory drug (NSAID) in patients with knee osteoarthritis: Design and protocol of a placebo-controlled, noninferiority, randomized withdrawal trial
Goulet JL, Buta E, Brennan M, Heapy A, Fraenkel L. Discontinuing a non-steroidal anti-inflammatory drug (NSAID) in patients with knee osteoarthritis: Design and protocol of a placebo-controlled, noninferiority, randomized withdrawal trial. Contemporary Clinical Trials 2017, 65: 1-7. PMID: 29198731, DOI: 10.1016/j.cct.2017.11.020.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdultAge FactorsAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalDisability EvaluationDouble-Blind MethodEquivalence Trials as TopicFemaleHumansMaleMeloxicamMiddle AgedOsteoarthritis, KneePain MeasurementPatient Education as TopicResearch DesignSeverity of Illness IndexSex FactorsSocial SupportYoung AdultConceptsNon-steroidal anti-inflammatory drugsUse of NSAIDsOA knee painKnee painKnee osteoarthritisAnti-inflammatory drugsWithdrawal trialCurrent non-steroidal anti-inflammatory drugsKnee OA painPainful knee osteoarthritisClasses of medicationsLower extremity disabilityTwo-week runFirst clinical trialVA healthcare systemOA painEligible subjectsSecondary outcomesPrimary outcomeGlobal ImpressionNSAID toxicityNoninferiority marginClinical trialsExtremity disabilityCommon causePilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer.
Kann B, Johung K, Cheng Y, Lam W, Liu S, Decker R, Higgins S. Pilot trial of KD018 with neo-adjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Clinical Oncology 2017, 35: e15162-e15162. DOI: 10.1200/jco.2017.35.15_suppl.e15162.Peer-Reviewed Original ResearchGI toxicityRectal cancerClinical studiesGrade 3Day 1Clinical stage T3-T4Concurrent chemo-radiation therapyPilot phase I trialPathologic partial responseStandardized pharmaceutical productsAdvanced rectal cancerPhase I trialStage T3-T4Favorable toxicity profileChemo-radiation therapyFirst clinical studyFirst clinical trialTraditional Chinese medicineAbdominal RTGI ailmentsN0-N2Po bidAccrual goalCTCAE v4.0Gastrointestinal toxicity
2013
The collateral circulation of the heart
Meier P, Schirmer SH, Lansky AJ, Timmis A, Pitt B, Seiler C. The collateral circulation of the heart. BMC Medicine 2013, 11: 143. PMID: 23735225, PMCID: PMC3689049, DOI: 10.1186/1741-7015-11-143.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseCollateral arteriesArtery diseaseCollateral circulationCoronary arteryOcclusive coronary artery diseaseRelevant protective roleEpicardial coronary arteriesFirst clinical trialIntracoronary pressure measurementsRecent pilot studyExternal counterpulsationEnd arteriesClinical trialsBlood supplyArteryProtective roleGranulocyte colonyAnastomotic vesselsPilot studyGrowth factorGold standardDiseasePressure measurementsVessels
2011
A critical role for macrophages in neovessel formation and the development of stenosis in tissue‐engineered vascular grafts
Hibino N, Yi T, Duncan DR, Rathore A, Dean E, Naito Y, Dardik A, Kyriakides T, Madri J, Pober JS, Shinoka T, Breuer CK. A critical role for macrophages in neovessel formation and the development of stenosis in tissue‐engineered vascular grafts. The FASEB Journal 2011, 25: 4253-4263. PMID: 21865316, PMCID: PMC3236622, DOI: 10.1096/fj.11-186585.Peer-Reviewed Original ResearchConceptsMacrophage infiltrationNeovessel formationGraft-related complicationsIncidence of stenosisTissue-engineered vascular graftsDevelopment of stenosisTransgenic mouse modelRole of macrophagesFirst clinical trialSmooth muscle cellsVascular graftsTEVG stenosisMacrophage infiltratesClodronate liposomesClinical trialsM1 macrophagesM2 phenotypeMurine modelMouse modelStenosisSeeded graftsRole of cellNatural historyMuscle cellsMacrophagesVascular tissue engineering: Towards the next generation vascular grafts
Naito Y, Shinoka T, Duncan D, Hibino N, Solomon D, Cleary M, Rathore A, Fein C, Church S, Breuer C. Vascular tissue engineering: Towards the next generation vascular grafts. Advanced Drug Delivery Reviews 2011, 63: 312-323. PMID: 21421015, DOI: 10.1016/j.addr.2011.03.001.Peer-Reviewed Original ResearchConceptsBone marrow-derived mononuclear cellsClinical trialsAutologous bone marrow-derived mononuclear cellsNext-generation vascular graftsMarrow-derived mononuclear cellsVascular graftsExcellent safety profileFirst clinical trialRisk of infectionBiodegradable tubular scaffoldsTissue engineering technologyPrimary graftSafety profileMononuclear cellsCardiovascular diseaseTubular scaffoldsCardiovascular surgeryGraftSynthetic vascular graftsVascular neotissue formationNeotissue formationContinued investigationTEVGsEngineering technologyTrials
2000
Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy
Abshire T, Brackmann H, Scharrer I, Hoots K, Gazengel C, Powell J, Gorina E, Kellermann E, Vosburgh E. Sucrose Formulated Recombinant Human Antihemophilic Factor VIII Is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. Thrombosis And Haemostasis 2000, 83: 811-816. PMID: 10896230, DOI: 10.1055/s-0037-1613925.Peer-Reviewed Original ResearchConceptsRFVIII-FSHome therapyAdverse eventsPharmacokinetic profileHemophilia ADrug-related adverse eventsRecombinant factor VIII productsIntermittent chest painFactor replacement therapyTreatment of bleedsSevere haemophilia AFirst clinical trialFactor VIII productsExcellent hemostatic controlSignificant adverse effectsFull-length rFVIIIChest painReplacement therapyClinical trialsViral inactivation stepsHemostatic controlExposure daysPatientsFactor VIIITherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply